Methamphetamine withdrawal induces activation of CRF neurons in the brain stress system in parallel with an increased activity of cardiac sympathetic pathways. by García-Carmona, JA et al.
1 
 
Methamphetamine withdrawal induces activation of CRF neurons in the 
brain stress system in parallel with an increased activity of cardiac 
sympathetic pathways 
Juan Antonio García-Carmona1,2* juanantonio.garcia8@um.es,  
Polymnia Georgiou3,4,  
Panos Zanos3,4,  
Alexis Bailey3,5,  
Maria Luisa Laorden1 
1
Department of Pharmacology, Faculty of Medicine 
University of Murcia 
Murcia, Spain 
2
Unit of Acute Psychiatry 
Reina Sofía University Hospital 
Av Intendente Jorge Palacios 1, 30003 Murcia, Spain 
3
Department of Biochemistry, Faculty of Health and Medical Sciences 
University of Surrey 
Guildford, UK 
4
Department of Psychiatry 
University of Maryland School of Medicine 
Baltimore, MD 21209, USA 
5
Institute of Medical and Biomedical Education 
St. George’s University of London 
London SW17 0R, UK 
 Abstract 
Methamphetamine (METH) addiction is a major public health problem in some 
countries. There is evidence to suggest that METH use is associated with increased risk 
of developing cardiovascular problems. Here, we investigated the effects of chronic 
METH administration and withdrawal on the activation of the brain stress system and 
cardiac sympathetic pathways. Mice were treated with METH (2 mg/kg, i.p.) for 
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10 days and left to spontaneous withdraw for 7 days. The number of corticotrophin-
releasing factor (CRF), c-Fos, and CRF/c-Fos neurons was measured by 
immunohistochemistry in the paraventricular nucleus of the hypothalamus (PVN) and 
the oval region of the bed nucleus of stria terminalis (ovBNST), two regions associated 
with cardiac sympathetic control. In parallel, levels of catechol-o-methyl-transferase 
(COMT), tyrosine hydroxylase (TH), and heat shock protein 27 (Hsp27) were measured 
in the heart. In the brain, chronic-METH treatment enhanced the number of c-Fos 
neurons and the CRF neurons with c-Fos signal (CRF
+
/c-Fos
+
) in PVN and ovBNST. 
METH withdrawal increased the number of CRF
+
 neurons. In the heart, METH 
administration induced an increase in soluble (S)-COMT and membrane-bound (MB)-
COMT without changes in phospho (p)-TH, Hsp27, or pHsp27. Similarly, METH 
withdrawal increased the expression of S- and MB-COMT. In contrast to chronic 
treatment, METH withdrawal enhanced levels of (p)TH and (p)Hsp27 in the heart. 
Overall, our results demonstrate that chronic METH administration and withdrawal 
activate the brain CRF systems associated with the heart sympathetic control and point 
towards a METH withdrawal induced activation of sympathetic pathways in the heart. 
Our findings provide further insight in the mechanism underlining the cardiovascular 
risk associated with METH use and proposes targets for its treatment. 
Juan Antonio García-Carmona and Polymnia Georgiou contributed equally to this work 
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 Introduction 
Methamphetamine (METH), or methylamphetamine, the N-methylated analogue of the 
psychostimulant amphetamine is widely abused in certain countries (Panenka et al. 
2013). METH use is extensive because of its relatively easy clandestine manufacture 
and low street cost and the health consequences of METH addiction are devastating 
(Gonzales et al. 2010; for review, see Wada 2011). Nonetheless, currently, there is no 
available pharmacotherapy for METH addiction (Ciccarone 2011). 
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Acutely, METH induces euphoric effects via the stimulation of dopamine, 
noradrenaline, and 5-hydroxytryptamine release in neurons of the brain through amine 
redistribution from synaptic vesicles to the cytoplasm and by reversing the action of 
monoamine transporters (Krasnova and Cadet 2009; Sulzer et al. 2005). Chronic use of 
METH leads to neurotoxic effects, e.g., degeneration of striatal dopaminergic neurons 
(Wagner et al. 1980), the formation of reactive oxygen species (Cubells et al. 1994; 
LaVoie and Hastings 1999; O’Dell et al. 1991; Yamamoto and Zhu 1998), and/or 
glutamate excitotoxicity as a consequence of METH-induced glutamate release in the 
striatum (Abekawa et al. 1994; Nash and Yamamoto 1992; Stephans and Yamamoto 
1994). In addition to the neurotoxic effects of METH, its use also causes adverse and 
potentially fatal effects on the cardiovascular system (for review, see Kaye et al. 2007). 
Specifically, chronic METH exposure is linked to a wide variety of cardiovascular 
disorders associated with impaired heart rate and vagal abnormalities, including 
tachycardia, hypertension, cardiomyopathy, coronary artery disease, prolonged QTc 
interval, and myocardial infarction (Ito et al. 2009; Henry et al. 2012). 
Similar to stress, METH withdrawal leads to the activation of the catecholaminergic 
system resulting in enhanced circulating catecholamine levels, which were shown to 
induce microfocal fibrosis damage of the heart (Kasch 1987). Noradrenergic neurons 
projecting from the brainstem are directly responsible for the sympathetic activation of 
the nervous system, including cardiovascular regulation through spinal cord 
innervations (Sawchenko and Swanson 1982). Neuronal firing rate in the brainstem is 
mediated by the activation of corticotrophin-releasing factor (CRF) fibers that project 
from the paraventricular nucleus of the hypothalamus (PVN) and the oval region of the 
bed nucleus of the stria terminalis (ovBNST) to the noradrenergic neurons located in the 
solitary tract and ventrolateral medulla (Stamatakis et al. 2014), thus implicating a key 
role for CRF in sympathetic cardiovascular regulation. In addition, the PVN and the 
ovBNST receive afferent projections from several limbic structures that are implicated 
in behavioral/stress-related responses, as well as cardiovascular control, such as the 
medial amygdala, the prefrontal cortex, and the lateral septum (Risold and Swanson 
1997; Ongur et al. 1998, Daniel and Rainnie 2016). 
The role of CRF in several brain regions including the amygdala, hypothalamus, 
septum, and BNST in drug addiction and stress regulation, as well as their interaction, 
has been well documented (Koob 2010). Nonetheless, the specific regulation of CRF in 
METH-induced cardiac alterations remains undetermined. Thus, given the severe 
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cardiovascular complications associated with chronic METH use, the investigation of 
the neuropathophysiology underlining the cardiovascular consequences of chronic 
METH use is warranted to shed light in the mechanism linking the CRF stress systems 
in brain regions associated with cardiovascular sympathetic control such as the PVN 
and the ovBNST with heart complications. 
Therefore, in the present study, we have evaluated the effects of chronic METH-
treatment and spontaneous withdrawal in the CRF stress system in the PVN and the 
ovBNST in brain. We firstly measured the number of neurons expressing CRF and/or c-
Fos in both brain areas following chronic METH administration and withdrawal. In 
addition, we assessed biochemical markers of sympathetic activation including soluble 
(S) and membrane-bound (MB)-catechol-o-methyl transferase (COMT), enzyme 
involved in the degradation of catecholamine, and tyrosine hydroxylase (TH) 
phosphorylated at Ser40 (THpSer40), the limiting enzyme in catecholamine synthesis, 
in the left ventricle of the heart. Moreover, levels of the heat shock protein (Hsp27) and 
the phosphorylated protein at serine 82 (pHSP27), which protect cells under stress 
conditions, were measured in the left ventricle. The left ventricle was selected as it 
receives sympathetic innervations from brainstem regions innervated by CRF neurons 
localized in PVN and ovBNST. 
 Materials and methods 
 Animals 
Male C57BL/6J mice (7 weeks old, 20–25 g, Charles River Laboratories, Kingston, 
UK) were housed in groups of three to four animals per box in a temperature-controlled 
environment with a 12-h light/dark cycle (lights on 06:00 a.m.). Food and water were 
available ad libitum. Mice were left to acclimatize in their new environment for 7 days 
prior to the experimental start and were handled daily by the experimenter. All 
experimental procedures were conducted in accordance with the UK Animal Scientific 
Procedures Act (1986). 
 Drugs and chemicals 
Methamphetamine was obtained from Sigma-Aldrich (Poole, UK); sodium dodecyl 
sulfate, polyacrylamide gel, and PVDF membranes were obtained from Bio-Rad 
Laboratory (Teknovas, Bilbao, Spain); and goat serum and nickel sulfate were from 
Sigma Aldrich (St. Louis, MO). 
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 Chronic steady-dose methamphetamine administration 
paradigm 
Mice were randomly divided into four groups: saline-, METH-treated, saline-
withdrawn, and METH-withdrawn animals. Chronic METH-treated animals were 
injected i.p. for 10 days with METH (2 mg/kg) (Sigma-Aldrich, Poole, UK), once per 
day (at 09:00 a.m.), in accordance with Georgiou et al. (2016). The chronic saline-
treated group was administered saline (10 ml/kg, i.p.) for 10 days, once per day (at 
09:00 a.m.). Saline- and METH-withdrawn animals were treated with the same 
administration paradigm and left to spontaneously withdrawal for 7 days in their home 
cages without any injections. Body weights of the animals were measured daily prior to 
drug treatment and during the withdrawal period at the same time of day. Mice were 
euthanized by a brief (30 s) exposure to CO2 1 h post-final injection for the chronic 
METH/saline administration groups or 7 days post-final injection for the withdrawal 
groups. The brains and hearts were rapidly removed, fresh-frozen, and immediately 
stored at − 80 °C until use for Western blot analysis, and immunohistochemistry 
quantification. 
 Hematoxylin and eosin staining for heart tissue sections 
To assess cardiac histology, the hematoxylin and eosin staining of heart tissue sections 
was used. Hearts were fixed in 10% neutral buffered formalin, dehydrated, and 
embedded in paraffin wax. Hearts were sectioned (5 μm thick) using a microtome 
(Reichert Jung 2040 Autocut) and stained with hematoxylin (Sigma Aldrich, Poole, 
UK) and eosin (VWR International Ltd., Poole, UK). Sections were examined for 
morphological changes such as hypertrophy, edema, and inflammatory cell infiltrate, 
and images were obtained by a light microscope. Analysis was performed by an 
experimenter blind to the treatment groups. 
 Western blot analysis 
Western blot analysis was performed for THpSer40, COMT, total Hsp27, and Hsp27 
phosphorylated at Ser82. Left ventricles of the hearts were dissected and were 
homogenized for 30 s using a homogenization buffer [phosphate-buffered saline, 2% 
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sodium dodecylsulfate (SDS), protease inhibitors (Roche, Germany), and phosphatase 
inhibitors (Calbiochem, Germany)]. Then, the samples were centrifuged at 10,000×g for 
10 min at 4 °C. Total protein concentrations were determined spectrophotometrically 
using the bicinchoninic acid method (Wiechelman et al. 1988). The optimum amount of 
protein to be loaded was determined in preliminary experiments by loading gels with 
increasing protein contents (25 to 100 mg) from samples of each experimental group. 
Equal amounts of protein (50 mg/lane) from each sample were loaded on a 10% SDS 
polyacrylamide gel (SDS-PAGE), electrophoresed, and transferred onto a 
polyvinylidenedifluoride (PVDF) membrane using a Mini Trans-Blot Electrophoresis 
Transfer Cell (Bio-Rad Lab., CA, USA). Non-specific binding of the antibodies was 
blocked by incubating the membranes in 1% bovine serum albumin (BSA) in Tris 
buffer saline Tween (TBST 10 mM Tris–HCl, pH 7.6, 150 mM NaCl, 0.05% Tween 
20). The blots were incubated overnight at 4 °C, with the following primary antibodies: 
polyclonal anti-TH phospho-Ser40 (1:500 dilution; AB5935, Millipore, USA), 
monoclonal anti-COMT (1:5000 dilution AB5873, Chemicon International, Temecula, 
MA, USA), polyclonal anti-total Hsp27 (1:500 dilution; sc-1048, Santa Cruz 
Biotechnology, Santa Cruz, CA, USA), and polyclonal anti-phospho-Ser
82
 Hsp27 
(1:500 dilution; ab39399, Abcam Ltd., Cambridge, UK) in TBST with BSA. After three 
10-min washings with TBST, the membranes were incubated with the corresponding 
peroxidase-labeled secondary antibodies for 1 h, at room temperature (anti-goat sc-2350 
for total Hsp27; anti-rabbit sc-2004 for Hsp27 phosphorylated at Ser 82 and TH 
phospho-Ser40; anti-mouse sc-2005 for COMT, Santa Cruz) at 1:5000 dilutions (Santa 
Cruz, USA). After washing with TBST, immunoreactivity was detected with an 
enhanced chemiluminescent Western blot detection system (ECL Plus, GE Healthcare, 
UK) and visualized by a Typhoon 9410 Variable Mode Imager (GE Healthcare). We 
used anti-total TH (1:1000 dilution; 62 kDa, AB152, Millipore, USA) and β-actin 
(1:1000 dilution, 45 kDa, Cell Signaling Technology, Inc., Beverly, MA, USA) as our 
loading control for all experiments and to obtain the ratios. Before re-probing, blots 
were stripped by incubation with stripping buffer (glycine 25 mM and SDS 1%, pH 2), 
for 1 h at 37 °C. Blots were subsequently reblocked and probed with total TH or B-actin 
overnight at room temperature. The ratio of Hsp27 (27 kDa)/B-actin, Hsp27 phosho-
Ser82 (27 kDa)/B-actin, TH phospho-Ser40 (60 kDa)/total TH, S-COMT (25 kDa)/B-
actin, and MB-COMT (30 kDa)/B-actin were plotted and analyzed by densitometry 
(AlphaImager, Nucliber, Madrid, Spain). Experimental and control samples were 
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included in the same blots, and relative variations between bands were calculated in the 
same image. 
 Double-labeling immunohistochemistry of c-Fos- and CRF-
positive neurons in the PVN and ovBNST 
Frozen brains were sectioned (20 μm thick; 300 μm apart) using a cryostat (Zeiss 
Microm 505E, Hertfordshire, UK) as previously described (Georgiou et al. 2015). For 
c-Fos/CRF double-label immunohistochemistry, PVN and ovBNST tissue sections from 
each mouse in each treatment group were processed as previously described (Garcia-
Carmona et al. 2013). Briefly, sections were incubated in primary rabbit anti-(c-Fos) 
(1:10,000 dilution; non-cross-reactive with Fos-B, Fra-1 or Fra-2; sc-52; Santa Cruz) 
and rabbit anti-CRF (1:500 dilution, a gift from Wylie Vale, The Salk Institute, USA) 
overnight at room temperature. After the primary anti-body incubation period, sections 
were incubated with the secondary anti-rabbit IgG (diluted 1:1000; Vector 
Laboratories). Antigens were visualized by a conventional avidin–biotin–
immunoperoxidase protocol using reagents from the Vectastain ABC Elite Kit (Vector 
Laboratories, Burlingame, CA) and 3,3′-diaminobenzidine (DAB) (Sigma Chemical, 
Madrid, Spain) as chromogen. c-Fos was visualized by using a mixture of NiSO4·6H2O 
(33.2 mg/ml), DAB (0.033%), and 0,014% H2O2 in 0.175 M sodium acetate solution 
(pH 7.5). The CRF–antibody–peroxidase complex was stained on 0.033% DAB and 
0.014H202 in 0.05 M Tris–HCl buffer. Tissue sections were transferred into Milli-Q 
water (Millipore) to stop the color reaction. Sections were dehydrated through graded 
alcohols cleared in xylene and cover slipped with DPX. 
 Co-localization of c-Fos immunoreactivity with CRF-
positive neurons 
Images of brain sections were captured using a video camera (DFC 290; Leica, Madrid, 
pain) on a light microscope (DM4000B; Leica) at × 20 and × 40 magnifications. The 
number of c-Fos and CRF immunoreactive neurons was counted by an observer blind to 
the treatment groups, using a computer-assisted image analysis system (QWIN; Leica) 
with an identical rectangular frame. Eight to ten sections from each mouse were counted 
bilaterally at distinct rostro-caudal levels of PVN or ovBNST obtaining an average. c-
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Fos-positive expression was identified as cells with dark blue deposits in the nucleus. 
CRF positive staining was shown as a brown cytoplasmic deposit. Double-labeled 
CRF/c-Fos neurons were counted in PVN and ovBNST. The CRF-positive cells without 
a visible nucleus (c-Fos-negative CRF cells) were also included in the analysis. A 
square field (129 μm) was superimposed on captured image for using as reference area. 
 Statistical analysis 
All the statistical analyses were performed using GraphPad Prism 6.0, and the results 
are expressed as the mean ± S.E.M. Data from all experiments were analyzed by two-
way ANOVA with treatment (saline, methamphetamine) and phase 
(chronic/withdrawal) as independent variables. ANOVAs were followed by Holm–
Sidak post-hoc test when significance was reached. Body weight changes were analyzed 
with repeated measures two-way ANOVA with factors “body weight” and “time 
(repeated factor).” Significance was set at p < 0.05. 
 
 Results 
 Effects of chronic methamphetamine and/or withdrawal on 
histopathological measures 
Histopathological examination of the heart revealed no morphological changes on the 
heart wall such as hypertrophy, which was calculated by the ratio of heart weight/body 
weight, edema, and inflammatory cell infiltrate following chronic METH administration 
and withdrawal (Fig. 1a–d). 
 Effects of chronic methamphetamine and/or withdrawal on 
body and heart weights 
Body weight of the animals was measured during the chronic METH administration and 
withdrawal. Two-way repeated measures ANOVA revealed no significant METH-
induced alterations on body weights during the chronic administration paradigm, as well 
as following withdrawal (treatment F[1,22] = 0.2501, p > 0.05; Fig. 1e). Heart weights 
were measured following euthanasia, and the relative heart weight was calculated as the 
ratio of heart/terminal body weight for each animal. Two-way ANOVA revealed no 
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significant differences between groups on the relative heart weights (phase 
F[1,23] = 0.0399, p > 0.05; treatment F[1,23] = 0.907, p > 0.05; Fig. 1f). 
 Number of c-Fos-/CRF-positive neurons following chronic 
methamphetamine and withdrawal in the PVN and ovBNST 
Changes in the number of c-Fos
+
/CRF
+
 neurons in the PVN (Fig. 2) and ovBNST 
(Fig. 3) were assessed using immunohistochemistry. Two-way ANOVA on the number 
a CRF
+
 neurons in the PVN revealed a significant effect of “treatment” (F[1,20] = 40.26, 
p < 0.001), “withdrawal” (F[1,20] = 12.00, p < 0.01), and “interaction” (F[1,20] = 7.79, 
p < 0.05). Holm–Sidak post-hoc test showed that METH withdrawal increases the 
number of CRF
+
 neurons compared to saline withdrawal (p < 0.001) and chronic METH 
administration (p < 0.01) (Fig. 2e). Two-way ANOVA on the c-Fos
+
 neurons in the 
PVN revealed a main effect of METH treatment (F[1,20] = 19.93, p < 0.01) and 
withdrawal (F[1,20] = 5.11, p < 0.05). Post-hoc test showed an increased (p < 0.01) 
number of c-Fos
+
 neurons after chronic METH treatment versus saline treatment and 
spontaneous METH withdrawal (Fig. 2f). Two-way ANOVA on the number of c-
Fos
+
/CRF
+
 neurons revealed a main effect of METH treatment (F[1,20] = 24.82, 
p < 0.001) and withdrawal (F[1,20] = 9,26, p < 0.01). Post-hoc test revealed that METH 
treatment and withdrawal enhanced (p < 0.001) the number of CRF
+
/c-Fos
+
 neurons. 
The increase in the number of CRF
+
/c-Fos
+
 neurons was higher (p < 0.001) after 
spontaneous withdrawal versus METH treatment (Fig. 2g). 
In the ovBNST (Fig. 3), two-way ANOVA on the number a CRF+ neurons revealed a 
significant effect of treatment (F[1,20] = 15.24, p < 0.001), withdrawal (F[1,20] = 14.13, 
p < 0.01), and interaction (F[1,20] = 10.43, p < 0.01). Holm–Sidak post-hoc test showed 
that METH withdrawal increases the number of CRF
+
 neurons compared to saline 
withdrawal (p < 0.001) and chronic METH administration (p < 0.001) (Fig. 3e). Two-
way ANOVA on the number a c-Fos
+
 (Fig. 3f) revealed a main effect of treatment 
(F[1,20] = 5.90, p < 0.05), withdrawal (F[1,20] = 12.99, p < 0.01), and interaction 
(F[1,20] = 7.59, p < 0.05). Post-hoc test indicates a significant (p < 0.01) increase of c-
Fos
+
 neurons in the chronic METH group versus saline treatment and spontaneous 
METH withdrawal (Fig. 3f). Two-way ANOVA on the number a c-Fos+/CRF+ revealed 
a main effect of treatment (F[1,20] = 24.82, p < 0.0001) and withdrawal (F[1,20] = 9.25, 
p < 0.01). Post-hoc test revealed that METH treatment and withdrawal enhanced 
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(p < 0.001) the number of CRF
+
/c-Fos
+
 neurons compared to their respective controls. 
The increase in the number of CRF
+
/c-Fos
+
 neurons was higher (p < 0.01) after 
spontaneous withdrawal versus METH treatment (Fig. 3g). 
 
 Effect of chronic methamphetamine administration and 
withdrawal on markers of sympathetic activity and cellular stress 
in the heart left ventricle 
We examined the effects of chronic METH treatment and withdrawal on the 
noradrenergic pathways innervating the heart in mice. Two-way ANOVA for S-COMT 
expression revealed a significant main effect of treatment (F[1,20] = 8.747, p < 0.01; 
Fig. 4a). Regarding MB-COMT quantification (Fig. 4b), two-way ANOVA revealed a 
significant main effect of treatment (F[1,20] = 11.77,p < 0.01). Post-hoc test revealed that 
chronic MET treatment or spontaneous withdrawal increased S-COMT (p < 0.05) and 
MB-COMT (p < 0.01) expression versus their respective control groups in the left 
ventricle (Fig. 4a, b). 
Since TH activity, a marker of catecholamine synthesis, is regulated by phosphorylation 
of specific serine residues, mainly serine 40 (Dunkley et al. 2004), we have evaluated 
the levels of this protein in the heart left ventricle of chronic METH-treated and -
withdrawn mice. Two-way ANOVA for THpSer40 expression revealed a significant 
main effect of treatment (F[1,19] = 5.63, p < 0.05), withdrawal (F[1,19] = 9.41, p < 0.01), 
and interaction (F[1,19] = 9.60, p < 0.01). Holm–Sidak post-hoc test showed increased 
(p < 0.001) THpSer40 levels in the METH-withdrawn group compared with the saline-
withdrawn group (p < 0.01) and the chronic METH-treated group (p < 0.01; Fig. 5). 
Chronic METH did not increase THpSer40 levels (p > 0.05). 
 Expression of Hsp27 and phospho-Hsp27 in chronic 
methamphetamine treatment and withdrawal 
We examined Hsp27 and pHSP27 expression, which is highly expressed in the heart 
(Latchman 2002), to determine the magnitude and severity of cellular stress during 
chronic METH treatment and withdrawal. Two-way ANOVA for Hsp27 expression 
revealed a significant main effect of withdrawal (F[1,21] = 5.39, p < 0.05). Since we have 
set a priori hypothesis that METH withdrawal will increase Hsp27 expression, we 
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performed planned comparisons to test this hypothesis. Post-hoc analysis revealed that 
METH withdrawal induced a significant increase in Hsp27 expression in the left 
ventricle compared with chronic METH-treated group (p < 0.05) and a close to 
significance increase compared with the saline withdrawal group (p = 0.06; Fig. 6a). 
Two-way ANOVA for pHSP27 revealed a significant effect of treatment 
(F[1,23] = 24.20,p < 0.001), withdrawal (F[1,23] = 16.59, p < 0.001), and a significant 
interaction (F[1,23] = 17.09, p < 0.01). METH withdrawal significantly enhanced 
pHSP27 compared to its respective control group (p < 0.001), as well as compared to 
the chronic METH-treated group (p < 0.01; Fig. 6b). 
 
 Discussion 
In the present study, we demonstrated that METH withdrawal induced an 
increase in CRF immunoreactivity and caused an increase of c-Fos signal in the CRF 
neurons of PVN and ovBNST. This neurotransmitter changes in the brain were 
accompanied by alterations of markers of sympathetic heart activation, as shown by an 
increase in THpSer40, as well as MB- and S-COMT in the left ventricle. No body 
weight or heart weight/histological changes were observed following chronic METH 
treatment or withdrawal. There was also evidence of cellular stress in the heart during 
METH withdrawal as indicated by the increased levels of Hsp27 in the left ventricle. 
The role of the ovBNST in the regulation of heart rate has been largely studied. 
In particular, microinfusion of CRF in this brain region increases heart rate during stress 
(Nijsen et al. 2001), via CRF1 and CRF2 receptors activation (Oliveira et al. 2015). The 
PVN has also been clearly identified as essential for the sympathetic activation of the 
heart (Yu et al. 2016; Deng et al. 2015). We have recently shown that this PVN 
mediated sympathetic activation is CRF1-dependent and proposed the existence of a 
plausible loop of CRF–noradrenaline between the PVN and the brainstem (Martinez-
Laorden et al. 2014; Garcia-Carmona et al. 2015). CRF and its analogues can also 
induce sympathetic heart and vasculature effect by increasing the secretion of 
noradrenaline and adrenaline from the sympathetic nervous system and adrenal medulla, 
respectively, and play a role within the heart as local mediators (Yang et al. 2010). 
Previous reports have demonstrated that drug withdrawal activates the CRF 
neurons of PVN and thus to modulate the HPA axis activity (Koob and Le Moal 2008). 
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However, in a previous study, we showed using an identical METH administration 
paradigm that chronic administration of METH induced an increase in corticosterone 
levels, which returned to baseline levels following a 7-day withdrawal period (Georgiou 
et al. 2016), suggesting a full recovery of METH-induced HPA activation following a 
7 day withdrawal period. Although the peripheral arm of the HPA axis might not be 
involved, in the present study, we found that METH withdrawal increased CRF and c-
Fos/CRF-positive neurons in both PVN and ovBNST. Activation of the brain stress 
system has been associated with elevated anxiety and a negative emotional state 
characteristic of drug withdrawal (Loogrip et al. 2011). Indeed, we previously showed 
that a 7-day withdrawal from chronic METH administration induced an anxiogenic 
phenotype in mice (Georgiou et al. 2016). Although it is not possible to determine a 
causal relationship between CRF activation in these brain regions and the anxiogenic 
phenotype, given the role of the CRF system in the PVN and ovBNST in stress 
regulation, it would be tempted to speculate a possible role of the CRF activation in the 
PVN and ovBNST in the emergence of these behavioral alterations. In line with our 
findings, previous studies showed a significant increase of the number of CRF-
containing neurons in PVN and ovBNST in morphine- (Nuñez et al. 2010), alcohol- 
(Sharko et al. 2016), and cocaine-withdrawn (Nobis et al. 2011) animals. Notably, PVN 
is considered the main source of stress-related neuroendocrine CRF release (Olive et al. 
2002) and withdrawal from drugs of abuse result in the dysregulation of the ovBNST 
neurons via a CRF-mediated mechanism (Francesconi et al. 2009), further supporting 
the role of the CRF neurotransmission within these brain regions in the modulation of 
addiction-associated stress/anxiety responses. 
It is well established that acute drug administration is able of enhance the 
expression of c-Fos (Motbey et al. 2012). This activation also takes place even with a 
stressor such as a needle prick (Kazakova et al. 2000). It is impossible to determine 
based on the results of the present study alone whether changes in c-Fos, CRF, etc. 
observed following METH administration are due to repeated METH treatment or due 
to an acute effect of the last METH injection. Nonetheless, the fact that increases in 
CRF
+
/c-Fos
+
 neurons take place a long time (7 days) after the last METH injection and 
not shortly (1 h) after the last injection of the drug makes it unlikely that alterations in 
these markers of stress are due to an acute injection of the drug. However, it is more 
difficult to determine whether the increase in c-Fos following chronic METH 
administration, an effect not observed following 7 days of withdrawal, is due to the 
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summation of repeated injections or rather acute METH injection alone and this is 
indeed a recognized limitation of our findings. 
The changes observed in the CRF activation were concomitant with an increase 
in makers of sympathetic activation such as THpSer40 levels as MB- and S-COMT in 
the heart following chronic METH treatment and withdrawal, supporting the activation 
of the sympathetic system within the heart. Interestingly, these alterations were 
observed at a time point when no alterations in corticosterone levels were observed as 
demonstrated in an identical METH administration and withdrawal paradigm (Georgiou 
et al. 2016), thus indicating that the changes observed in the present study are 
independent of the HPA axis activity. This is of particular interest given the role of CRF 
in the HPA axis and highlights the presence of distinct CRF regulatory mechanisms in 
different brain regions. Although COMT activity in the brain has been associated with 
increased vulnerability for drug abuse including METH, nicotine, and morphine (Li et 
al. 2004; Beuten et al. 2005; Ersche et al. 2011) and reward processing (Tunbridge et al. 
2013), the present study is the first to assess and show a possible role of COMT in the 
periphery and specifically in the heart following METH administration and withdrawal. 
In addition to the changes observed in COMT levels, we have also observed METH-
induced enhancement of Hsp27 levels and Hsp27 phosphorylation at Ser82 specifically 
during withdrawal and not following the chronic treatment with the drug. Given the role 
of Hsp27 in modulating oxidative stress and apoptosis (Mymrikov et al. 2011), this 
finding suggests that METH withdrawal induces marked cellular stress responses that 
might be associated with a myocardial damage (Dettmeyer et al. 2009). This increase in 
Hsp27 levels in the heart might be a compensatory mechanism to counteract METH-
induced oxidative stress, since Hsp27 reacts to stress by acting as a chaperone (Ammon-
Treiber et al. 2004; Peart and Gross 2006), preventing oxidative damage (Rogalla et al. 
1999), acting as an anti-apoptotic molecule to prevent cell death (Mehlen et al. 1997), or 
regulating actin cytoskeleton reorganization (Robinson et al. 2010). Similar induction of 
HSP27 has been reported following administration and/or withdrawal of other drugs of 
abuse (Toth et al. 2010; Dietrich et al. 2007). The mechanism underlining this HSP27 
immunoreactivity cannot be determined from this study alone, but given the evidence 
showing that administration of a selective inhibitor of ERK activation prevented 
morphine withdrawal-induced Hsp27 phosphorylation at Ser82 (Martínez-Laoden et al. 
2012), it is tempting to speculate that the effect of METH withdrawal on Hsp27 might 
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be regulated through the extracellular signal-regulated protein kinase (ERK) signaling. 
While it requires further investigation, it is highly plausible that the observed changes 
within the brain regions associated with sympathetic control of the heart could mediate 
the observed markers of sympathetic activation in the heart. In support of this, a causal 
relationship has been observed between CRF1 activation in selected brain regions such 
as amygdala, ovBNST, and PVN and stress-induced sympathetic activation of the heart 
(Nijsen et al. 2000; Chu et al. 2004). In addition, we have previously demonstrated that 
heart sympathetic activation is CRF1-dependent during morphine withdrawal 
(Martinez-Laorden et al. 2014, Garcia-Carmona et al. 2015), supporting the role of the 
central CRF in the peripheral alterations in the heart in drug dependent individuals. 
Chronic METH use has been linked to a variety of cardiovascular complications 
associated with increased sympathetic activation such as hypertension and 
cardiomyopathy. Our current results strongly suggest that increases in COMT, TH, and 
HSP27 in the heart together with the concomitant increase in CRF activation of 
ovBNST and PVN, regions both known to be associated with cardiovascular regulation, 
may at least partly play a role in the biology underlining these complications. 
Overall, in this study, we demonstrated alterations on markers of cardiac 
sympathetic activity, central CRF system, and cardiac Hsp levels following chronic 
METH administration and/or withdrawal, which are addiction phases normally 
associated with anxiety and stress reactivity (Koob and Volkow 2016). Our findings 
provide further insight into the specific biological mechanisms underlying the 
devastating cardiovascular consequences of METH use and abstinence and provide 
information for potential targets for the development of novel and effective 
pharmacotherapies for the treatment of the cardiovascular- and stress-related 
complications associated with METH use and withdrawal. Further work needs to be 
carried out to verify the role of increased brain CRF signaling on the observed changes 
in the heart. 
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Fig. 1 Microscopic heart histology staining. Mice received one daily injection of saline 
or methamphetamine (METH; 2 mg/kg; i.p.) and were let to spontaneous withdraw for a 
period of 7 days. Images represent immunohistochemical hematoxylin-eosin staining of 
myocardiocytes from a chronic saline, b chronic METH, c saline withdrawal, and d 
METH withdrawal. Scale bar 50 μm. e Effect of saline or methamphetamine(METH) 
treatment on body weight gain in mice. f Effect of chronic methamphetamine treatment 
or withdrawal on the terminal heart weight. Data are the mean ± SEM. Repeated 
measures two-way ANOVA (e) and two-way ANOVA (f) 
Fig. 2 Effect of chronic METH administration and withdrawal on number of CRF
+
, c-
Fos
+
, and c-Fos
+
/CRF
+
 neurons in the paraventricular nucleus of the hypothalamus 
(PVN). Increased c-Fos (c-Fos
+
) in corticotropin-releasing factor (CRF
+
) neurons in 
methamphetamine (METH) treated groups in the PVN. Representative 
immunohistochemical images of c-Fos
+
/CRF
+
 neurons in the PVN from a chronic 
saline-, b saline-withdrawn, d chronic METH-treated, and d METH-withdrawn mice 
(scale bar 100 μm). Red arrows = c-Fos+/CRF+ neurons; black arrows = CRF+ neurons; 
green arrows = c-Fos
+
. Quantitative immunohistochemical analysis of e CRF
+
, f c-Fos
+
, 
and g c-Fos
+
/CRF
+
 neurons in the PVN of mice treated with a 10-day steady-dose 
METH administration paradigm and in mice-withdrawn for 7 days. Data are expressed 
as mean ± S.E.M. ***p < 0.001 versus saline withdrawal; 
++
p < 0.01, 
+++
p < 0.001 
versus chronic METH treatment; 
&&
p < 0.01, 
&&&
p < 0.001 versus chronic saline 
treatment. Two-way ANOVA followed by Holm–Sidak post-hoc test (color figure 
online) 
Fig. 3 Effect of chronic METH administration and withdrawal on the number of CRF, 
c-Fos and c-Fos/CRF neurons in the bed nucleus of the stria terminalis (ovBNST). 
Increased c-Fos (c-Fos
+
) in corticotropin-releasing factor (CRF
+
) neurons in 
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methamphetamine (METH)-treated groups in the mice. Representative 
immunohistochemical images of c-Fos
+
/CRF
+
 neurons in the PVN from a chronic 
saline-, b saline-withdrawn, c chronic METH-treated, and d METH-withdrawn mice 
(scale bar 100 μm). Red arrows = c-Fos+/CRF+ neurons; black arrows = CRF+ neurons; 
green arrows = c-Fos
+
. Quantitative immunohistochemical analysis of e CRF
+
, f c-Fos
+
, 
and g c-Fos
+
/CRF
+
 neurons in the PVN of mice treated with a 10-day steady-dose 
METH administration paradigm and in mice-withdrawn for 7 days. Data are expressed 
as mean ± S.E.M. ***p < 0.001 versus saline withdrawal; 
++
p < 0.01, 
+++
p < 0.001 
versus chronic METH treatment; 
&&
p < 0.01, 
&&&
p < 0.001 versus chronic saline 
treatment. Two-way ANOVA followed by Holm–Sidak post-hoc test (color figure 
online) 
Fig. 4 COMT levels following chronic methamphetamine administration and 
withdrawal. Western-blotting analysis of a soluble-COMT (S-COMT) and b 
membrane-COMT (MB-COMT) in the left ventricle of chronic methamphetamine 
(METH) or withdrawn mice and their respective saline (Sal) controls. Immunoreactivity 
of S-COMT or MB-COMT is expressed as a percentage of control (defined as 100%). 
Data are the mean ± SEM. *p < 0.05,**p < 0.01 versus saline withdrawal; 
&
p < 0.05, 
&&
p < 0.01 versus chronic saline treatment. Two-way ANOVA followed by Holm–
Sidak post-hoc test 
Fig. 5 THpSer40 levels following chronic methamphetamine administration and 
withdrawal. Western-blotting analysis of tyrosine hydroxylase phosphorylated at serine 
40 (THpSer40) in the left ventricle of chronic methamphetamine (METH) or withdrawn 
mice and their respective saline (Sal) controls. Immunoreactivity of THpSer40 is 
expressed as a percentage of control (defined as 100%). Data are the mean ± SEM. 
***
p < 0.001 versus saline withdrawal; 
++
p < 0.01 versus chronic METH treatment. 
Two-way ANOVA followed by Holm–Sidak post-hoc test 
Fig. 6 Hsp27 and phosphor-Hsp27 levels following chronic methamphetamine 
administration and withdrawal. Western-blotting analysis of total a Hsp27 (Hsp27) and 
b phospho-Hsp27 (pHsp27) in the left ventricle in chronic methamphetamine (METH) 
or withdrawn mice and their respective controls treated with saline (Sal). 
Immunoreactivity of Hsp27 or pHsp27 is expressed as a percentage of control (defined 
as 100%). Data are the mean ± SEM. ***p < 0.001 versus saline withdrawal; 
+
p < 0.05, 
++
p < 0.01 versus chronic METH treatment. Two-way ANOVA followed by Holm–
Sidak post-hoc test 
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